organophosphonates has been researched along with Acute Coronary Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parker, WAE; Storey, RF | 1 |
| Angiolillo, DJ; Capodanno, D; Franchina, GA; Milluzzo, RP | 1 |
| Beavers, CJ; Dobesh, PP; Effoe, SA | 1 |
1 review(s) available for organophosphonates and Acute Coronary Syndrome
| Article | Year |
|---|---|
Selatogrel, a novel P2Y
Topics: Acute Coronary Syndrome; Animals; Drug Development; Humans; Injections, Subcutaneous; Organophosphonates; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Pyrimidines; Thrombosis | 2020 |
2 other study(ies) available for organophosphonates and Acute Coronary Syndrome
| Article | Year |
|---|---|
Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y
Topics: Acute Coronary Syndrome; Blood Platelets; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Injections, Subcutaneous; Organophosphonates; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrimidines | 2020 |
Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Humans; Organophosphonates; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrimidines | 2022 |